Peptidomimetic inhibitors of the human cytomegalovirus protease

Journal of Medicinal Chemistry

Volumn 40, Issue 25, 1997, Pages 4113-4135

  Ogilvie, William ^a   Bailey, Murray ^a   Poupart, Marc André ^a   Abraham, Abraham ^a   Bhavsar, Amit ^a   Bonneau, Pierre ^a   Bordeleau, Josée ^a   Bousquet, Yves ^a   Chabot, Catherine ^a   Duceppe, Jean Simon ^a   Fazal, Gulrez ^a   Goulet, Sylvie ^a   Grand Maître, Chantal ^a   Guse, Ingrid ^a   Halmos, Ted ^a   Lavallée, Pierre ^a   Leach, Michael ^a   Malenfant, Eric ^a   O'Meara, Jeff ^a   Plante, Raymond ^a   Plouffe, Céline ^a   Poirier, Martin ^a   Soucy, François ^a   Yoakim, Christiane ^a   Déziel, Robert ^a   more..

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

N1 (3,3,3 TRIFLUORO 1 METHYL 2 OXOPROPYL) 2 [[2 METHYL 1[[2 METHYL 1 (METHYLCARBOXAMIDO)PROPYL] CARBOXAMIDO]PROPYL]CARBOXAMIDO]BUTANEDIAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; DRUG POTENCY; ENZYME ASSAY; HUMAN CYTOMEGALOVIRUS; PHYSICAL CHEMISTRY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; HUMANS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15144347039     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970104t     Document Type: Article

References (64)

1. Gold, E.; Nankervis, G. A. Viral Infections of Humans: Epidemiology and Control, 2nd ed.; Evans, A. S., Jr., Ed.; Plenum Publishing Corp.: New York, 1982; pp 167-186.
2. (a) Mocarski, E. S., Jr. Virology 2; Lippincott-Raven: Philadelphia, PA, 1995; pp 2447-2492.
3. (b) Britt, W. J.; Alford, C. A. Virology 2; Lippincott-Raven: Philadelphia, PA, 1995; pp 2493-2525.
4. (c) Fields, B. N.; Knipe, D. M. Virology, Vol. 2; Raven Press: New York, 1990; pp 1878-2010 (Chapters 64-73).
5. (a) Pass, R. F.; Stagno, S.; Myers, G. J.; Alford, C. A. Outcome of symptomatic congenital cytomegalovirus infection: Results of long-term longitudinal follow-up. Pediatrics 1980, 66, 758-762.
6. (b) Conboy, T. J.; Pass, R. F.; Stagno, S.; Alford, C. A.; Myers, G. J.; Britt, W. J.; McCollister, F. P.; Summers, M. N.; McFarland, C. E.; Boll, T. J. Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J. Pediatrics 1987, 111, 343-348.
7. (a) Gibson, W. Structural and nonstructural proteins of strain Colburn cytomegalovirus. Virology 1981, 111, 516-537.
8. (b) Liu, F.; Roizman, B. The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate. J. Virol. 1991, 65, 5149-5156.
9. (c) Newcomb, W. W.; Brown, J. C. Structure of the herpes simplex virus capsid: effects of extraction within guanidine hydrochloride and partial reconstruction of extracted capsids. J. Virol. 1991, 65, 613-620.
10. (a) Gibson, W.; Welch, A. R.; Hall, M. R. T. Assemblin, a herpes virus serine maturational proteinase and new molecular target for antivirals. Perspect. Drug Disc. Des. 1994, 2, 413-426 and references therein,
11. (b) Holwerda, B. C. Herpesevirus proteases: targets for novel antiviral drugs. Antiviral Res. 1997, 35, 1-21
12. In addition to the M- and R-sites, two more cleavage sites (I and m) are known for HCMV protease. Both of these sites are located within the catalytic domain. See refs 5 and 6.
13. (a) Holwerda, B. C.; Wittwer, A. J.; Duffin, K. L.; Smith, C.; Toth, M. V.; Carr, L. S.; Wiegand, R. C.; Bryant, M. L. Activity of two-chain recombinant human cytomegalovirus protease. J. Biol. Chem. 1994, 269, 25911-25913.
14. (b) Stevens, J. T.; Mapelli, C.; Tsao, J.; Hail, M.; O'Boyle, D.; Weinheimer, S. P.; Dilanni, C. L. In vitro proteolytic activity and active-site identification of the human cytomegalovirus protease. Eur. J. Biochem. 1994, 226, 361-367.
15. (c) Dilanni, C. L.; Stevens, J. T.; Bolgar, M.; O'Boyle, D. R.; Weinheimer, S. P.; Colonno, D. J. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J. Biol. Chem. 1994, 269, 12672-12676.
16. Welch, A. R.; McNally, L. M.; Hall, M. R. T.; Gibson, W. Herpesvirus proteinase: site-directed mutagenesis used to study maturational, release, and inactivation cleavage sites of precursor and to identify a possible catalytic site serine and histidine. J. Virol. 1993, 67, 7360-7372.
17. (a) Tong, L.; Qian, C.; Massariol, M.-J.; Bonneau, P. R.; Cordingley, M. G.; Lagacé, L. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 1996, 272-275.
18. (b) Qiu, X.; Gulp, J. S.; DiLella, A. G.; Hellmig, B.; Hoog, S. S.; Janson, C. A.; Smith, W. W.; Abdel-Meguid, S. S. Unique fold and active site in cytomegalovirus protease. Nature 1996, 275-279.
19. (c) Shieh, N.-S.; Kurumball, R. G.; Stevens, A. M.; Stegeman, R. A.; Sturman, E. J.; Pak, J. Y.; Wittwer, A. J.; Palmier, M. O.; Wiegand, R. C.; Holwerda, B. C.; Stallings, W. C. Three-dimensional structure of human cytomegalovirus protease. Nature 1996, 279-282.
20. (d) Chen, P.; Tsuge, H.; Almassy, R. J.; Gribskov, C. L.; Katoh, S.; Vanderpool, P. L.; Margosiak, S. A.; Pinko, C.; Matthews, D. A.; Kan, C.-C. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 1996, 86, 835-843.
21. (a) Preston, V. G.; Coates, J. A.; Rixon, F. J. Identification and characterization of a herpes simplex virus gene product required for encapsulation of virus DNA. J. Virol. 1983, 45, 1056-1064.
22. (b) Gao, M.; Matusick-Kumar, L.; Hurlburt, W.; Ditusa, S.; Newcomb, W. W.; Brown, J. R.; McCann, P. J., III; Deckman, I.; Colonno, R. J. The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. J. Virol. 1994, 68, 3702-3712.
23. For nonpeptidic inhibitors of HCMV protease, see: (a) Chu, M.; Mierzwa, R.; Truumees, I.; King, A.; Patel, M.; Pichardo, J.; Hart, A.; Dasmahapatra, B.; Das, P. R.; Puar, M. S. SCH65676: A Novel fungal metabolite with the inhibitory activity against the cytomegalovirus protease, Tetrahedron Lett. 1996, 37, 3943-3946. (b) Baum, E. Z.; Ding, W.-D.; Siegel, M. M.; Hulmes, J.; Bebernitz, G. A.; Sridharan, L.; Tabei, K.; Krishnamurthy, G.; Carofigilio, T.; Groves, J. T.; Bloom, J. D.; DiGrandi, M.; Bradley, M.; Ellestad, G.; Seddon, A. P.; Gluzman, Y. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 1996, 35, 5847-5855. (c) Pinto, I. L.; West, A.; Debouck, C. M.; DiLella, A. G.; Gorniak, J. G.; O'Donnell, K. C.; O'Shannessy, D. J.; Patel, A.; Jarvest, R. L. Novel, selective mechanism based inhibitors of the herpes proteases. Bioorg. Med. Chem. Lett. 1996, 6, 2467-2472. (d) Shu, Y.-Z.; Ye, Q.; Kolb, J. M.; Huang, S.; Veitch, J. A.; Lowe, S. E.; Manly, S. P. Bripiodionen, a new inhibitor of human cytomegalovirus protease from Streptomyces sp. WC76599. J. Nat. Prod. 1997, 60, 529-532
24. For nonpeptidic inhibitors of HCMV protease, see: (a) Chu, M.; Mierzwa, R.; Truumees, I.; King, A.; Patel, M.; Pichardo, J.; Hart, A.; Dasmahapatra, B.; Das, P. R.; Puar, M. S. SCH65676: A Novel fungal metabolite with the inhibitory activity against the cytomegalovirus protease, Tetrahedron Lett. 1996, 37, 3943-3946. (b) Baum, E. Z.; Ding, W.-D.; Siegel, M. M.; Hulmes, J.; Bebernitz, G. A.; Sridharan, L.; Tabei, K.; Krishnamurthy, G.; Carofigilio, T.; Groves, J. T.; Bloom, J. D.; DiGrandi, M.; Bradley, M.; Ellestad, G.; Seddon, A. P.; Gluzman, Y. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 1996, 35, 5847-5855. (c) Pinto, I. L.; West, A.; Debouck, C. M.; DiLella, A. G.; Gorniak, J. G.; O'Donnell, K. C.; O'Shannessy, D. J.; Patel, A.; Jarvest, R. L. Novel, selective mechanism based inhibitors of the herpes proteases. Bioorg. Med. Chem. Lett. 1996, 6, 2467-2472. (d) Shu, Y.-Z.; Ye, Q.; Kolb, J. M.; Huang, S.; Veitch, J. A.; Lowe, S. E.; Manly, S. P. Bripiodionen, a new inhibitor of human cytomegalovirus protease from Streptomyces sp. WC76599. J. Nat. Prod. 1997, 60, 529-532
25. For nonpeptidic inhibitors of HCMV protease, see: (a) Chu, M.; Mierzwa, R.; Truumees, I.; King, A.; Patel, M.; Pichardo, J.; Hart, A.; Dasmahapatra, B.; Das, P. R.; Puar, M. S. SCH65676: A Novel fungal metabolite with the inhibitory activity against the cytomegalovirus protease, Tetrahedron Lett. 1996, 37, 3943-3946. (b) Baum, E. Z.; Ding, W.-D.; Siegel, M. M.; Hulmes, J.; Bebernitz, G. A.; Sridharan, L.; Tabei, K.; Krishnamurthy, G.; Carofigilio, T.; Groves, J. T.; Bloom, J. D.; DiGrandi, M.; Bradley, M.; Ellestad, G.; Seddon, A. P.; Gluzman, Y. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 1996, 35, 5847-5855. (c) Pinto, I. L.; West, A.; Debouck, C. M.; DiLella, A. G.; Gorniak, J. G.; O'Donnell, K. C.; O'Shannessy, D. J.; Patel, A.; Jarvest, R. L. Novel, selective mechanism based inhibitors of the herpes proteases. Bioorg. Med. Chem. Lett. 1996, 6, 2467-2472. (d) Shu, Y.-Z.; Ye, Q.; Kolb, J. M.; Huang, S.; Veitch, J. A.; Lowe, S. E.; Manly, S. P. Bripiodionen, a new inhibitor of human cytomegalovirus protease from Streptomyces sp. WC76599. J. Nat. Prod. 1997, 60, 529-532
26. For nonpeptidic inhibitors of HCMV protease, see: (a) Chu, M.; Mierzwa, R.; Truumees, I.; King, A.; Patel, M.; Pichardo, J.; Hart, A.; Dasmahapatra, B.; Das, P. R.; Puar, M. S. SCH65676: A Novel fungal metabolite with the inhibitory activity against the cytomegalovirus protease, Tetrahedron Lett. 1996, 37, 3943-3946. (b) Baum, E. Z.; Ding, W.-D.; Siegel, M. M.; Hulmes, J.; Bebernitz, G. A.; Sridharan, L.; Tabei, K.; Krishnamurthy, G.; Carofigilio, T.; Groves, J. T.; Bloom, J. D.; DiGrandi, M.; Bradley, M.; Ellestad, G.; Seddon, A. P.; Gluzman, Y. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 1996, 35, 5847-5855. (c) Pinto, I. L.; West, A.; Debouck, C. M.; DiLella, A. G.; Gorniak, J. G.; O'Donnell, K. C.; O'Shannessy, D. J.; Patel, A.; Jarvest, R. L. Novel, selective mechanism based inhibitors of the herpes proteases. Bioorg. Med. Chem. Lett. 1996, 6, 2467-2472. (d) Shu, Y.-Z.; Ye, Q.; Kolb, J. M.; Huang, S.; Veitch, J. A.; Lowe, S. E.; Manly, S. P. Bripiodionen, a new inhibitor of human cytomegalovirus protease from Streptomyces sp. WC76599. J. Nat. Prod. 1997, 60, 529-532
27. Abraham, N. A.; Fazal, G.; Ferland, J.-M.; Rakhit, S.; Gauthier, J. A new solid-phase strategy for the synthesis of mammalian glucagon. Tetrahedron Lett. 1991, 32, 577-580.
28. (a) Pfitzner, K. E.; Moffatt, J. G. Sulfoxide-carbodiimide reactions. I. A facile oxidation of alcohols. J. Am. Chem. Soc. 1965, 87, 5661-5670.
29. (b) Pfitzner, K. E.; Moffatt, J. G. Sulfoxidecarbodiimide reactions. II. Scope of the oxidation reaction. J. Am. Chem. Soc. 1965, 87, 5670-5678.
30. Poupart, M.-A.; Fazal, G.; Goulet, S.; Mar, L. T. Solid-phase synthesis of peptidyl trifluoromethyl ketones; presented at the 213th American chemical society National Meeting, San Fraucisco, April 1997.
31. G-Val-Pro-Val pentafluoroethyl ketones. J. Med. Chem. 1994, 37, 4538-4554.
32. Thaisrivongs, S.; Pals, P. T.; Kati, W. M.; Turner, S. R.; Thomasco, L. M.; Watt, W.; Design and synthesis of potent and specific renin inhibitors containing diflurostatine, difluorstatone, and related analogues. J. Med. Chem. 1986, 24, 2080-2087.
33. (a) Edwards, P. D.; Meyer, E. F., Jr.; Vijayalakshmi, I.; Tuthill, P. A.; Andisik, D. A.; Gomes, B.; Strimpler, A. Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl α-ketobenzoxazoles, and the X-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole. J. Am. Chem. Soc. 1992, 114, 1854-1863.
34. (b) Edwards, P. D.; Zottola, M. A.; Davis, M.; Williams, J.; Tuthill, P. A. Peptidyl α-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl α-ketobenzoxazoles. J. Med. Chem. 1995, 38, 3972-3982.
35. (c) Edwards, P. D.; Wolanin, D. J.; Andisik, D. W.; Davis, M. W. Peptidyl α-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency. J. Med. Chem. 1995, 38, 76-85.
36. (d) Tsutsumi, S.; Okonogi, T.; Shibahara, A.; Ohuchi, S.; Hatsushiba, E.; Patchett, A. A.; Christensen, B. G. Synthesis and structure-activity relationships of peptidyl α-keto heterocycles as novel inhibitors of prolyl endopeptidase. J. Med. Chem. 1994, 37, 3492-3502.
37. Dess, D. B.; Martin, J. C. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 48, 4155-4156.
38. Miller, M. J.; Mattingly, P. G.; Morrison, M. A.; Kerwin, J. F., Jr. Synthesis of β-lactams from hydroxamic acids. J. Am. Chem. Soc. 1980, 102, 7026-7032.
39. Gage, J. R.; Evans, D. A. Diastereoselective aldol condensation using a chiral oxazolidinone auxiliary: (2S*,3S*)-3-hydroxy-3-phenyl-2-methylpropanoic acid. Org Synth. 1989, 68, 83-91.
40. Evans, D. A.; Britton, T. C.; Ellman, J. A.; Dorow, R. L. The asymmetric synthesis of α-amino acids. Electrophilic azidation of chiral imide enolates, a practical approach to the synthesis of (R)- and (S)-azido carboxylic acids. J. Am. Chem. Soc. 1990, 112, 4011-4030.
41. (a) Burck, P. J.; Berg, D. H.; Luk, T. P.; Sassmanshausen, M. L.; Wakulchik, M.; Smith, D. P.; Hsiung, H. M.; Bekker, G. W.; Gibson, W.; Villareal, E. C. Human cytomegalovirus maturational proteinase: expression in Escherichia coli, purification, and enzymatic characterization by using peptide substrate mimics of natural cleavage sites. J. Virol. 1994, 68, 2937-2946.
42. (b) Sardana, V. V.; Wolfgang, J. A.; Veloski, C. A.; Long, W. J.; LeGrow, K.; Wolanski, B.; Emini, E. A.; LaFemina, R. L. Peptide substrate cleavage specificity of the human cytomegalovirus protease. J. Biol. Chem. 1994, 269, 14337-14340.
43. (c) Handa, B. K.; Keech, E.; Conway, E. A.; Broadhurst, A.; Ritchie, A. Design and synthesis of a quenched fluorogenic peptide substrate for human cytomegalovirus proteinase. Antiviral Chem. Chemother. 1995, 6, 255-261.
44. m) on 76 determinations.
45. (a) Burkhart, J. P.; Koehl, J.; Mehdi, S.; Durham, S. L.; Janusz, M. J.; Huber, E. W.; Angelastro, M. R.; Sunder, S.; Metz, W. A.; Shuro, P. W.; Chen, T.-M.; Bey, P.; Cregge, R. J.; Peet, N. P. Inhibition of human neutrophil elastase. 3. An orally active enol acetate prodrug. J. Med. Chem. 1995, 38, 223-233.
46. (b) Curley, K.; Pratt, R. F. Structure of an α-keto β-amino acid, 3-(phenylacetamido)pyruvic acid, and its methyl ester in the solid state and in organic and aqueous solvents. J. Org. Chem. 1997, 62, 4479-4483.
47. Assigned configurations were based on inhibitory activity.
48. m relative to those substrates incorporating alanine. See refs 22b,c.
49. A number of other amide substitutions based on compounds 39 and 51 were tested, however no improvement in inhibitor potency was noted relative to 51.
50. Mehdi, S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg. Chem. 1993, 21, 249-259.
51. i value of approximately 40 nM was extrapolated from the Dixon plot.
52. Edwards, P. D.; Bernstein, P. R. Synthetic inhibitors of elastase. Med. Res. Rev. 1994, 14, 128-194 and references therein.
53. Bonneau, P.; Grand-Maître, C.; Greenwood, D.; Lagacé, L.; LaPlante, S. R.; Massariol, M.-J.; Ogilvie, W. W.; O'Meara, J.; Kawai, S. H. Evidence of a conformation al change in the human cytomegalovirus protease upon binding of peptidyl activated carbonyl inhibitors. Biochemistry 1997, 36, 12644-12652.
54. 50 values greater than 250 μM.
55. Skiles, J. W.; Fuchs, V.; Miao, C.; Sorcek, R.; Grozinger, K. G.; Mauldin, S. C.; Vitous, J.; Mui, P. W.; Jacober, S.; Chow, G.; Matteo, M.; Skoog, M.; Weldon, S. T.; Possanza, G.; Keirns, J.; Letts, G.; Rosenthal, A. Inhibition of human leukocyte elastase (HLE) by N-substituted peptidyl trifluoromethyl ketones. J. Med. Chem. 1992, 35, 641-662.
56. Murphy, A. M.; Dagnino, Jr., R.; Vallar, P. L.; Trippe, A. J.; Sherman, S. L.; Lumpkin, R. H.; Tamura, S. Y.; Webb, T. R. automated synthesis of peptide C-terminal aldehydes. J. Am. Chem. Soc. 1992, 114, 3156.
57. (a) Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Synthesis and anti-tumor activity of topologically-related analogues of flavoneacetic acid. Anti-Cancer Drug Des. 1987, 4, 161-169.
58. (b) Gibson, G. P. VII-Nitro derivatives of o-cresol. J. Chem. Soc. 1925, 127, 43-49.
59. Oleksyszyn, J.; Subotkowska, L.; Mastalerz, P. Diphenyl 1-aminoalkanephosphonates. Synthesis 1979, 985-986.
60. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254
61. Cornish-Bowden, A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and noncompetitive inhibitors. Biochem. J. 1974, 137, 143-144.
62. Turk, S. R.; Shipman, C., Jr.; Nassiri, R.; Genzlinger, G.; Krawczyk, S. H.; Townsend, L. B.; Drach, J. C. Pyrrolo[2,3-d]-pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 1987, 31, 544-550.
63. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 1986, 89, 271-277.
64. o will be published separately.